MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
ADMA Biologics, Inc. (NASDAQ: ADMA)*
Organization & Developments: ADMA
Parents
ADMA Biologics, Inc. (NASDAQ: ADMA)*
Children
*ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection
*Late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases.
2018: ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?_seekingalpha.com
2018: FDA Rejects ADMA's BIVIGAM Drug Substance But Approves Drug Product? - ADMA Biologics Inc (NASDAQ:ADMA)
2019: ADMA Biologics: Under-The-Radar Biotech With Huge Potential Upside_seekingalpha.com
2020: ADMA Biologics: Another Quarter Of Progress And Another Dip To Buy
2020: ADMA Biologics: Feeling Very Bullish After Preliminary Q4 2019 Results_seekingalpha.com
2021: ADMA Biologics: Sell-Off Provides Buying Opportunity Ahead Of Projected Growth
2022: Adma Biologics: Understanding The Risks Of Blood Plasma Collection_ seekingalpha.com
2023: ADMA Biologics: Achieving Important Inflection Points (NASDAQ:ADMA)
2024: ADMA Biologics Set to Join S&P SmallCap 600 Index
2024: ADMA Biologics: A Compelling GARP Stock For Biotech Investors
2024: ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV_ seekingalpha.com
2024: ADMA Biologics: On A Roll Entering 2024_ seekingalpha.com
2024: ADMA Biologics: Riding High On ASCENIV's Success_ seekingalpha.com
2024: Biotech Hangs On To Top Spot On This List, And It Even Outshines Nvidia
2024: Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge
2024: Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)_ seekingalpha.com
2025: ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
Jumps
*Key People: Adma
Finance & Acquisition: Adma